Simon Chowdhury, MD, PhD

Chi KN et al. Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). ASCO GU 2021;Abstract 11.

Freedland SJ et al. Real-world utilization of advanced therapies and racial disparity among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis. ASCO 2021;Abstract 5073.

George DJ et al. Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings. ASCO 2021;Abstract 5074.

Shore ND et al. Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses. ASCO 2020;Abstract 5547.

Tanya B Dorff, MD

Agarwal N et al. Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). ASCO 2021;Abstract 5068.

Colomba E et al. ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC). ASCO 2021;Abstract 5046.

Gillessen S et al. Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis. ASCO 2020;Abstract 5002.

Thiery-Buillemin A et al. Impact of abiraterone acetate plus prednisone or enzalutamide on patient-reported outcomes in patients with metastatic castration-resistant prostate cancer: Final 12-mo analysis from the observational AQUARiUS study. Eur Urol 2020;77(3):380-7. Abstract

Matthew R Smith, MD, PhD

Fizazi K et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 2020;383(11):1040-9. Abstract

Shore ND et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 2020;382(23):2187-96. Abstract

Smith MR et al. Apalutamide and overall survival in prostate cancer. Eur Urol 2020;79(1):150-8. Abstract

Sternberg CN et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2020;382(23):2197-206. Abstract